Skip to content

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03645057
Enrollment
92
Registered
2018-08-24
Start date
2019-02-20
Completion date
2021-08-01
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time. The goal of this study is to detect changes in PROs and caregiver burden during treatment for atopic dermatitis of moderate or less severity. The study design will allow us to correlate PROs and caregiver burden with treatment response and disease improvement in children.

Detailed description

Atopic dermatitis (AD) is a common, chronic skin disease affecting 20% of children and 10% of adults worldwide (1-3). Children with AD often develop the disease within the first five years of life, which is a critical time for physical and psychosocial development (4). AD impacts an individual's physical, mental, and social health. Anxiety, itch, sleep disturbance, and depression have been associated with low quality of life scores. Childhood AD also affects the emotional, financial, physical, and social well-being of parents or caregivers (4). Individuals caring for a child with AD report sleep deprivation, poor social support, and stress about parenting (1, 4). Utilizing patient-reported outcomes (PROs) in clinic can provide meaningful data to monitor disease activity and response to different interventions, with the ultimate goal to improve quality of life for the patient and their family members or caregivers. Additionally, PROs can help us better understand the burden of AD. It is still unclear which PROs are most relevant for atopic dermatitis. This study will evaluate the utility of several PROs to monitor response to two different topical ointments, crisaborole (Eucrisa™) and tacrolimus 0.03%, to better understand the impact of these two non-steroidal topical treatments on overall health of children with AD of moderate or less severity and their caregivers.

Interventions

This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.

This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.

Sponsors

University of Rochester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time.

Eligibility

Sex/Gender
ALL
Age
2 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

Pediatric Subjects: 1. Male and female subjects of inclusive ages of 2 to 15 years (inclusive) at screening visit. 2. Diagnosis of ≤moderate atopic dermatitis or eczema (ISGA 2 or 3 and ≥3% BSA, excluding scalp). 3. If subject is taking or prescribed antihistamines, subject must be on stable dose of antihistamines. 4. If subject is taking or prescribed topical steroids, subject must be on stable dose of topical steroids. 5. If taking a systemic anti-inflammatory medication for atopic dermatitis or other condition, subject must be on stable dose of the systemic anti-inflammatory medication for six weeks prior to enrollment. 6. If subject is currently taking or prescribed tacrolimus or crisaborole, or other steroid-sparring medication, subject must agree to two week (i.e., 14 days) washout period prior to randomization and Baseline Assessment for study. 7. Caregiver (i.e., adult parent or guardian) must agree to participate in the study with the patient. e) Subject must be able to read and speak English. f) Subject ages ≥8 years, is able to give assent. Caregiver Subjects: 1. Subject must be at least 18 years old and the parent or guardian of the eligible pediatric subject. 2. Subject must be able to read and speak English. 3. Subject must be able to give informed consent.

Exclusion criteria

1. Pediatric subjects \<2 years old or \>15 years old are not eligible for participation in this study. 2. Pediatric subjects with a diagnosis with another skin disease (i.e., not atopic dermatitis or eczema) are excluded to prevent confounding of results. 3. Pediatric subjects currently on systemic anti-inflammatory therapy for atopic dermatitis or other indication are excluded. 4. Caregiver subject \<18 years old are excluded. 5. Pediatric subject participation without caregiver participation is not allowed.

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in PROMIS Pain Interference-Children (Adaptive Test)baseline to 12 weeksThis is a patient reported outcome measure for pain interference in pediatric patients. This is a computer adaptive test consisting of 4-12 questions related to how pain interferes with daily activities. The number of questions a patient answers depends on how he or she answers each question. The overall domain score ranges from 0 to100 with a score of 50 representing the average score for the general population. Higher scores indicate greater pain interference. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This measure was completed electronically on an iPad using REDCap.
Mean Change in Children's PROMIS Pediatric Itch Short-Formbaseline to 12 weeksThis is a patient-reported outcome measure for Itch in pediatric patients that consists of 8 fixed items items, spanning four domains (general, activity, mood/sleep, and scratching behavior). Each item is scored on using 1 = No Itch, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very Severe. The range of the scale is 1 to 5 with higher numbers indicating worse outcome. A total score, representing overall itch-related quality of life, is scored by taking the average (i.e., divide by 8) of the sum of all 8 items. Therefore, total itch scores range between 1 and 5, with higher scores indicating worse impact of itch on quality of life. The measure was completed electronically on an iPad using REDCap.

Secondary

MeasureTime frameDescription
Mean Change in Children's Sleep Habits QuestionnaireBaseline to 12 WeeksThis patient-reported outcome measure was completed by the caregiver using an iPad. This is a validated 22 item questionnaire consisting of 4 subscales: Bedtime, Sleep Behavior, Waking During the Night, and Morning Wake Up. The patient/parent will answer each item choosing from: Always if something occurs every night; Usually if it occurs 5 or 6 times a week; Sometimes if it occurs 2 to 4 times a week; Rarely if it occurs once a week; and Never if it occurs less than once a week. Each question is scored on a 3-point scale as 1 = Usually and Always (5-7 times/week); 2 = Sometimes (2-4 times/week); or 3 = Rarely and Never (0-1 time/week). The scores are combined from each subscale to generate a Total Sleep Disturbance Score, which can range from 22 (minimum) to 66 (maximum). The higher the score, the greater the sleep disturbance. A Total Sleep Disturbances score over 28 represent clinically significant sleep disturbance.
Mean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test)baseline to 12 weeksThis patient-reported outcome measure s will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to depressive symptoms. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater depressive symptoms. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.
Mean Change in Children's Eczema Area & Severity Index (EASI)baseline to 12 weeksClinician rated the severity of atopic dermatitis using the EASI. The EASI is a tool used to measure the extent (area) and severity of AD. It does not include a grade for dryness or scaling and includes only inflamed areas. The area score is a 7-point scale representing the percentage of skin affected by AD for each body region. The severity score is recorded for each of the four regions of the body and is the sum of the intensity scores for four signs. The four signs include redness, thickness, scratching, and lichenification. The intensity scores are performed using a 4-pont scale. The final EASI score is the sum of the total scores for each region. Add up the total scores for each region to determine the final EASI score. The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores represent worse AD severity.
Mean Change in PROMIS Anxiety-children (Adaptive Test)baseline to 12 weeksThis patient-reported outcome measure will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to anxiety. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater anxiety. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.
Mean Change in Children's Dermatology Life Quality Indexbaseline to 12 weeksThis patient-reported outcome measure will be completed using an iPad. The 10-item questionnaire designed for use in parents of children (i.e., ages 4-17) to obtain information on children's quality of life. Each question relates to a component of quality of life: Symptoms/Feelings (items 1-2); Leisure (items 4-6); School (item 7); Relationships (items 3-8); Sleep (item 9), and Treatment (item 10). Children answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher the scores, the greater burden on quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.

Other

MeasureTime frameDescription
Mean Change in Caregiver Burden Inventorybaseline to 12 weeksThe CBI is a 24-item, five-subscale Caregiver Burden Inventory (CBI) and demonstrates its use as a diagnostic tool for caregiver burden. The five subscales include: Time Dependency, Development, Physical Health, Emotional Health, and Social Relationships. Each subscale contains 4-5 items which are statements of feelings. Caregivers use a 5-point scale, anchored by 0 = Never and 4 = Nearly Always, to show how often the statement describes his/her feelings. Overall scores can range from 0 (minimum) to 96 (maximum), where a score near or above 36 indicates significant burden. Higher scores indicate greater caregiver burden (i.e., worse outcome). All subscales have a maximum score of 20, except Physical Health which has a maximum score of 16. Subscale scores and item scores help identify the underlying cause of caregiver burden. This measure will be completed electronically on an iPad using REDCap.
Mean Change in Family Dermatology Life Quality Indexbaseline to 12 weeksThe FDLQI is a 10-item questionnaire designed for adult family members of a patient with a skin disease. It measures the impact of the patient's skin disease on the family member's quality of life. The caregiver will answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher scores indicate worse quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30. This measure will be completed electronically on an iPad using REDCap.

Countries

United States

Participant flow

Recruitment details

This study enrolled child patients and caregiver (i.e., parent) dyads. Child patients with mild to moderate atopic dermatitis were enrolled based on the inclusion and exclusion criteria (see eligibility criteria). A caregiver (i.e., parent) of each child had to agree to participate in the trial.

Pre-assignment details

There were 47 patient/caregiver dyads (i.e., 94 subjects total = 47 child patients with 47 caregivers). If the child patient was already actively using cisaborole or tacrolimus 0.03% for their atopic dermatitis, child patient underwent a two week wash out before baseline assessment and randomization. One dyad was lost to follow up prior to randomization. Therefore, 46 dyads were randomized to one of the two study arms.

Participants by arm

ArmCount
Crisaborole-children
The topical treatment will be applied to all affected areas twice daily for 12 weeks. Crisaborole: This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
23
Tacrolimus-children
The topical treatment will be applied to all affected areas twice daily for 12 weeks. Tacrolimus 0.03% Ointment: This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
23
Crisaborole-caregiver
This was a dyad study. A caregiver was enrolled for each child.
23
Tacrolimus-caregiver
This was a dyad study. A caregiver was enrolled for each child.
23
Total92

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
6 Weeks to 12 WeeksLost to Follow-up0101
Baseline to Six WeeksLost to Follow-up5252
Baseline to Six WeeksWithdrawal by Subject1010
Randomization to BaselineLost to Follow-up1010

Baseline characteristics

CharacteristicTacrolimus-caregiverTotalCrisaborole-caregiverTacrolimus-childrenCrisaborole-children
Age, Continuous
caregivers
36.9 years
STANDARD_DEVIATION 8.4
37.0 years
STANDARD_DEVIATION 7.6
37.3 years
STANDARD_DEVIATION 5.9
Age, Continuous
children
8.8 years
STANDARD_DEVIATION 3.7
8.3 years
STANDARD_DEVIATION 4.1
9.3 years
STANDARD_DEVIATION 3.4
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants13 Participants5 Participants2 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants77 Participants17 Participants21 Participants18 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants2 Participants1 Participants0 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants2 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants2 Participants1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
9 Participants36 Participants9 Participants9 Participants9 Participants
Race (NIH/OMB)
More than one race
1 Participants7 Participants1 Participants2 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants10 Participants4 Participants1 Participants4 Participants
Race (NIH/OMB)
White
11 Participants35 Participants8 Participants10 Participants6 Participants
Region of Enrollment
United States
23 participants92 participants23 participants23 participants23 participants
Sex: Female, Male
Female
19 Participants64 Participants19 Participants11 Participants15 Participants
Sex: Female, Male
Male
4 Participants28 Participants4 Participants12 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 21
other
Total, other adverse events
2 / 163 / 21
serious
Total, serious adverse events
0 / 160 / 21

Outcome results

Primary

Mean Change in Children's PROMIS Pediatric Itch Short-Form

This is a patient-reported outcome measure for Itch in pediatric patients that consists of 8 fixed items items, spanning four domains (general, activity, mood/sleep, and scratching behavior). Each item is scored on using 1 = No Itch, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very Severe. The range of the scale is 1 to 5 with higher numbers indicating worse outcome. A total score, representing overall itch-related quality of life, is scored by taking the average (i.e., divide by 8) of the sum of all 8 items. Therefore, total itch scores range between 1 and 5, with higher scores indicating worse impact of itch on quality of life. The measure was completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Children's PROMIS Pediatric Itch Short-Form-0.3 score on a scaleStandard Deviation 0.8
Tacrolimus 0.03%Mean Change in Children's PROMIS Pediatric Itch Short-Form-0.4 score on a scaleStandard Deviation 0.8
p-value: 0.433Wilcoxon rank sum test
Primary

Mean Change in PROMIS Pain Interference-Children (Adaptive Test)

This is a patient reported outcome measure for pain interference in pediatric patients. This is a computer adaptive test consisting of 4-12 questions related to how pain interferes with daily activities. The number of questions a patient answers depends on how he or she answers each question. The overall domain score ranges from 0 to100 with a score of 50 representing the average score for the general population. Higher scores indicate greater pain interference. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This measure was completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in PROMIS Pain Interference-Children (Adaptive Test)-6.4 T-scoreStandard Deviation 10.4
Tacrolimus 0.03%Mean Change in PROMIS Pain Interference-Children (Adaptive Test)-6.8 T-scoreStandard Deviation 9.3
p-value: 0.836Wilcoxon rank sum test
Secondary

Mean Change in Children's Dermatology Life Quality Index

This patient-reported outcome measure will be completed using an iPad. The 10-item questionnaire designed for use in parents of children (i.e., ages 4-17) to obtain information on children's quality of life. Each question relates to a component of quality of life: Symptoms/Feelings (items 1-2); Leisure (items 4-6); School (item 7); Relationships (items 3-8); Sleep (item 9), and Treatment (item 10). Children answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher the scores, the greater burden on quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Children's Dermatology Life Quality Index-1.1 score on a scaleStandard Deviation 4
Tacrolimus 0.03%Mean Change in Children's Dermatology Life Quality Index-3.6 score on a scaleStandard Deviation 4.2
p-value: 0.073Wilcoxon rank sum test
Secondary

Mean Change in Children's Eczema Area & Severity Index (EASI)

Clinician rated the severity of atopic dermatitis using the EASI. The EASI is a tool used to measure the extent (area) and severity of AD. It does not include a grade for dryness or scaling and includes only inflamed areas. The area score is a 7-point scale representing the percentage of skin affected by AD for each body region. The severity score is recorded for each of the four regions of the body and is the sum of the intensity scores for four signs. The four signs include redness, thickness, scratching, and lichenification. The intensity scores are performed using a 4-pont scale. The final EASI score is the sum of the total scores for each region. Add up the total scores for each region to determine the final EASI score. The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores represent worse AD severity.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Children's Eczema Area & Severity Index (EASI)-2.4 score on a scaleStandard Deviation 2.9
Tacrolimus 0.03%Mean Change in Children's Eczema Area & Severity Index (EASI)-1.9 score on a scaleStandard Deviation 3
p-value: 0.577Wilcoxon rank sum test
Secondary

Mean Change in Children's Sleep Habits Questionnaire

This patient-reported outcome measure was completed by the caregiver using an iPad. This is a validated 22 item questionnaire consisting of 4 subscales: Bedtime, Sleep Behavior, Waking During the Night, and Morning Wake Up. The patient/parent will answer each item choosing from: Always if something occurs every night; Usually if it occurs 5 or 6 times a week; Sometimes if it occurs 2 to 4 times a week; Rarely if it occurs once a week; and Never if it occurs less than once a week. Each question is scored on a 3-point scale as 1 = Usually and Always (5-7 times/week); 2 = Sometimes (2-4 times/week); or 3 = Rarely and Never (0-1 time/week). The scores are combined from each subscale to generate a Total Sleep Disturbance Score, which can range from 22 (minimum) to 66 (maximum). The higher the score, the greater the sleep disturbance. A Total Sleep Disturbances score over 28 represent clinically significant sleep disturbance.

Time frame: Baseline to 12 Weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Children's Sleep Habits Questionnaire-1.7 score on a scaleStandard Deviation 6
Tacrolimus 0.03%Mean Change in Children's Sleep Habits Questionnaire-1.3 score on a scaleStandard Deviation 7
p-value: 0.989Wilcoxon rank sum test
Secondary

Mean Change in PROMIS Anxiety-children (Adaptive Test)

This patient-reported outcome measure will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to anxiety. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater anxiety. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in PROMIS Anxiety-children (Adaptive Test)-5.0 T-scoreStandard Deviation 9.8
Tacrolimus 0.03%Mean Change in PROMIS Anxiety-children (Adaptive Test)-6.8 T-scoreStandard Deviation 8.4
p-value: 0.565Wilcoxon rank sum test
Secondary

Mean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test)

This patient-reported outcome measure s will be completed by the child patient electronically on an iPad using computer adaptive test (CAT). The CAT consists of 4-12 questions on feelings related to depressive symptoms. The number of questions a patient answers depends on how he or she answers each question. The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population. Higher scores indicate greater depressive symptoms. A score above 55 is considered clinically significant for each domain. A score change of 5 or more is considered a clinically important change in domain severity. This PRO was completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test)-4.0 T-scoreStandard Deviation 7.4
Tacrolimus 0.03%Mean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test)-5.8 T-scoreStandard Deviation 9.5
p-value: 0.479Wilcoxon rank sum test
Other Pre-specified

Mean Change in Caregiver Burden Inventory

The CBI is a 24-item, five-subscale Caregiver Burden Inventory (CBI) and demonstrates its use as a diagnostic tool for caregiver burden. The five subscales include: Time Dependency, Development, Physical Health, Emotional Health, and Social Relationships. Each subscale contains 4-5 items which are statements of feelings. Caregivers use a 5-point scale, anchored by 0 = Never and 4 = Nearly Always, to show how often the statement describes his/her feelings. Overall scores can range from 0 (minimum) to 96 (maximum), where a score near or above 36 indicates significant burden. Higher scores indicate greater caregiver burden (i.e., worse outcome). All subscales have a maximum score of 20, except Physical Health which has a maximum score of 16. Subscale scores and item scores help identify the underlying cause of caregiver burden. This measure will be completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Caregiver Burden Inventory-1.3 score on a scaleStandard Deviation 7.2
Tacrolimus 0.03%Mean Change in Caregiver Burden Inventory-4.2 score on a scaleStandard Deviation 6.8
p-value: 0.439Wilcoxon (Mann-Whitney)
Other Pre-specified

Mean Change in Family Dermatology Life Quality Index

The FDLQI is a 10-item questionnaire designed for adult family members of a patient with a skin disease. It measures the impact of the patient's skin disease on the family member's quality of life. The caregiver will answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30). Higher scores indicate worse quality of life. The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30. This measure will be completed electronically on an iPad using REDCap.

Time frame: baseline to 12 weeks

ArmMeasureValue (MEAN)Dispersion
CrisaboroleMean Change in Family Dermatology Life Quality Index-2.6 score on a scaleStandard Deviation 4
Tacrolimus 0.03%Mean Change in Family Dermatology Life Quality Index-3.6 score on a scaleStandard Deviation 2.9
p-value: 0.242Wilcoxon rank sum test

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026